MedTrace Logo

Comparison of VA Guided Versus OCT Guided TER Using Aflibercept for Diabetic Macular Edema (AVOCT Study)

NCT03394573 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 110

Last updated 2021-03-18

No results posted yet for this study

Summary

This study will evaluate the effectiveness of aflibercept (Eylea®) using two different treatment protocols in patients with vision loss from diabetic macular edema. While one group will be treated with an optical coherence tomography (OCT) guided 'treat and extend' regimen, the other group will be treated according to a visual acuity (VA) guided 'treat and extend' protocol. The patients will be randomized into two treatment arms using an automated randomization algorithm.

Conditions

Interventions

OTHER

OCT guided treatment arm

Intravitreal injection of Aflibercept for DME OCT guided

OTHER

VA guided treatment arm

Intravitreal injection of Aflibercept for DME VA guided

Sponsors & Collaborators

  • Insel Gruppe AG, University Hospital Bern

    lead OTHER

Principal Investigators

  • Martin Zinkernagel, MD, PhD · University of Bern, Switzerland

  • Marion Munk, MD, PhD · University of Bern, Switzerland

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-09-16
Primary Completion
2021-02-01
Completion
2021-02-01

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03394573 on ClinicalTrials.gov